

MOROCCAN PHARMACEUTICAL CORPORATION "COOPER PHARMA" IN THE FIGHT AGAINST COVID-19

Benarafa Ibrahim Amin, El-Assri Abdeladim

Scientific supervisor Seniuk I.V.

National University of Pharmacy, Kharkiv, Ukraine

Introduction. After the World Health Organization (WHO) recognized the SARS-CoV-2 coronavirus outbreak as a public health emergency of international concern on January 30, 2020, it became possible to register COVID-19 vaccines on an emergency basis. Vaccines from leading pharmaceutical manufacturers have been used to combat the coronavirus in different countries around the world for the second year: BioNTech/Pfizer vaccine (USA), Moderna vaccine (USA), Oxford AstraZeneca vaccine (Great Britain), Sinopharm vaccine (China), Covaxin vaccine (India). In addition to vaccines, other methods and forms of fighting the "plague of the 21st century" are being created. Various forms of drugs (pills, injections, etc.) aimed at the prevention and treatment of COVID-19 disease are created. The Kingdom of Morocco is no exception, the well-known company "Cooper Pharma" also has successes on the front with the fight against coronavirus infection. Together with the United Arab Emirates, Cold & Flu Guard, a oral and nasal product is being produced which has proven successful in the prevention and treatment of COVID-19.

Oral Science International (OSI) is an innovation-driven company dedicated to developing and commercializing innovative bio-technologies, providing solutions to oral/nasal infections and inflammation. Oral Science International has a strong and passionate leadership team committed to innovative oral care and infection control technologies that enhance quality of life for people of all ages.

The aim of the study. To acquaint the scientific community with the use of an innovative, oral and nasal medicinal prepatent of plant origin, the technology of which was successfully launched by the Moroccan company "Cooper Pharma".

Methods of research. Websites of the company "Cooper Pharma" and the drug "Flavoba Cold & Flu Guard" were used [1, 2].

Main results. Innovative natural broad spectrum organic barrier is needed to prevent viral respiratory infection. Cooper Pharma and OSI signed a distribution agreement to market Flavoba Cold & Flu Guard. Under the terms of this agreement, OSI grants Cooper Pharma exclusive right to distribute Flavoba Cold & Flu Guard in Morocco and the United Arab Emirates (UAE). Cooper Pharma and Affiliates will employ their sales, marketing and e-commerce expertise to distribute Flavobac Cold & Flu Guard once product registration is obtained from the Moroccan and UAE health authorities.

Flavobac Cold & Flu Guard will become an essential part of Cooper Pharma's medical solutions, to protect children, parents, health care professionals and society against respiratory viruses including SARS-CoV-2 which causes COVID-19. "Cooper Pharma is committed to help reducing the impact of respiratory viral infection" said Ayman Cheikh-Lahlou, the CEO of Cooper Pharma.

Christian Sauvageau, OSI's President, said: "We are immensely proud of this opportunity to be working with such a forward thinking company as Cooper Pharma. We have seen the complete determination of Cooper Pharma to commercialise

innovative solutions and are so pleased to be working with them. We are also thankful to The Harel Group for identifying Cooper Pharma as a strategic partner and for facilitating the full transaction process from introduction to the execution of the final agreements with Cooper Pharma."



Flavobac Cold & Flu Guard is a formulation based on substance obtained from natural source. It combats viruses by interfering with their ability to adhere to the oral and nasal mucosa. Flavobac Cold & Flu Guard has been shown to kill "99.8% of the SARS-CoV-2 in 5 minutes

as well as many other respiratory viruses such as human Coronavirus, Influenza virus, Rhinovirus, and RSV. Flavobac Cold & Flu Guard™ is already registered in Europe, Canada and the USA. Efforts are underway to allow it to be used across the world. For more information consult [1].

The presented medication includes:

- Glycerine. A demulcent (derived from the Latin: demulcere "caress") is an agent that forms a soothing film over a mucous membrane, in this case your mouth and throat;
- High Molecular Weight Hyaluronic Acid. Naturally occurring polymer;
- Bioflavonoids, mint flavor, disodium phosphate anhydrous, stevia, cetylpyridinium chloride, sodium hyaluronate.

Viruses & bacteria are naturally neutralized and removed before developing into full blown illness. This drug can be used by adults and children from 5 years old. The drug does not contain genetically modified organisms and can be purchased without a doctor's review.

"Cooper Pharma is proud to receive distribution rights for Flavobac Cold & Flu Guard from our partner OSI so that we can help people and health care professionals to protect themselves against respiratory viral infection, while respecting of course and above all the health recommendations in terms of prevention and treatment against respiratory viruses and in particular SARS-CoV-2" said Ayman Cheikh-Lahlou, the CEO of Cooper Pharma. "Innovative broad spectrum barrier to help reducing viral spread and viral loads is an important new option to protect against respiratory viruses. Flavobac Cold & Flu Guard can neutralize viruses that have entered the nose and mouth and act as "local sanitizers" to destroy viruses before they have the opportunity to cause an infection. As the leading pharmaceutical company in Morocco, Cooper Pharma is glad to provide people with a new tool to safeguard themselves against respiratory viruses", said Ayman Cheikh-Lahlou.

Conclusions. Morocco's pharmaceutical facilities are well developed and capable of producing drugs that are highly relevant and in demand in the pharmaceutical market, particularly during a pandemic COVID-19.

References

1. Cold & Flu Guard creates a barrier where viruses & bacteria enter the body www.coldandfluguard.com.
2. Cooper Pharma. <http://cooperpharma.ma/en/>.